NOVO — Januar 2025
-
Sydbank om Novo: Fuldstændig fair kursreaktion på stærke vægttabsdata https://proinvestor.com/investornyt/1269139/sydbank-om-novo-fuldstaendig-fair-kursreaktion-pa-staerke-vaegttabsdata
-
Novos markedsværdi steg 183 mia. kr. efter stærke fedmedata https://proinvestor.com/investornyt/1269198/novos-markedsvaerdi-steg-183-mia-kr-efter-staerke-fedmedata
-
detalje, der "blot gør dagens nye resultater endnu mere imponerende." https://www.shareholders.dk/nyhed/novo-aktien-i-markant-stigning-efter-nye-data?utm_source=Aktionærens Nyhedsbrev&utm_campaign=be4509cbe1-20-07-2024_COPY_01&utm_medium=email&utm_term=0_bfc53fad21-be4509cbe1-90602917
-
Godmorgen
-
Novo Nordisk’s Amycretin: A Glimpse into the Future of GLP-1 Weight Loss Treatments https://www.onthepen.com/post/novo-nordisk-s-amycretin-a-glimpse-into-the-future-of-glp-1-weight-loss-treatments?utm_campaign=e6280513-1189-4af4-8ad5-bb1922b1e58a&utm_source=so&utm_medium=mail&cid=713e80cd-1fa6-468e-90d7-68fd62c5df0e
-
'Virker usandsynligt, at Novo Nordisk rammes af potentiel toldsats, siger analytiker' Søren Løntofts vurdering. NB: Indslaget fra 22/1 2025.
https://nyheder.tv2.dk/live/udland/2025-01-18-trump-i-det-hvide-hus?entry=87246090-06e0-4e85-b939-4c550c316c73 -
Fra Reuters "Veru said on Monday its
experimental drug, in combination with Novo Nordisk's
weight-loss treatment Wegovy, helped preserve muscle in older
patients with obesity, meeting the main goal of a mid-stage
study.
The study was testing Veru's oral drug, enobosarm, in
patients aged 60 and above. The drug targets androgen hormones,
which play a role in body development and reproductive health.
Patients who received the drug in combination with
Wegovy lost 71% less lean muscle on average than -
Novo sagsøgt af investor efter data fra fedmeforsøg med Cagrisema https://proinvestor.com/investornyt/1270031/novo-sagsogt-af-investor-efter-data-fra-fedmeforsog-med-cagrisema
-
Trump truer big pharma: https://x.com/FinanceLancelot/status/1884023740826280053
-
Novo får kursmål løftet med 10 pct. https://proinvestor.com/investornyt/1270270/novo-far-kursmal-loftet-med-10-pct
-
FDA approves Novo Nordisk’s diabetes drug Ozempic for chronic kidney disease, expanding its use
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind